Amy Rothberg, clinical professor of internal medicine in the Division of Metabolism, Endocrinology and Diabetes at the University of Michigan, says it also helps improve outcomes in people with type 2 diabetes and cardiorenal (heart and kidney) conditions, similar to semaglutide
A phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 demonstrated substantial weight loss in adults with obesity, and phase 3 trials are currently ongoing (see ClinicalTrials
Further research showed that GLP-1 reduced blood sugar levels in mammals, making it a promising candidate for diabetes medication
Elashoff (79) also suggested that, compared with other common hypoglycemic drugs, GLP-1RA may increase the risk of chronic pancreatitis and then change the levels of cellular inflammatory factors and reactive oxygen species, thus increasing the risk of pancreatic cancer
GLP-1s help you lose weight by curbing appetite and improving how your body handles food